Stock Track | Amphastar Pharmaceuticals Plunges 8.24% After-Hours on Q1 Earnings Miss, Lower Prices and Higher Costs

Stock Track05-08 08:03

Amphastar Pharmaceuticals' stock experienced a 24-hour plunge of 8.24% in post-market trading.

The sharp decline followed the company's release of disappointing first-quarter financial results. Amphastar reported adjusted earnings per share of $0.42, significantly missing the analyst consensus estimate of $0.70. Revenue of $171.17 million also fell short of expectations, while GAAP net income plummeted 75% year-over-year to $6.4 million.

The earnings miss was driven by lower average selling prices for key products including BAQSIMI, glucagon, phytonadione, and epinephrine, which reduced gross margin. Additionally, higher manufacturing expenses from facility expansion and increased research & development costs, including a $2 million licensing payment, further pressured profitability.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment